Health Condition 1: F42- Obsessive-compulsive disorder
Conditions
Interventions
Intervention1: Ketamine: Route of administration - Intravenous
Dose - 0.5 mg/kg bodyweight
Proper monitoring of vitals and emergence of adverse effects - atleast 2 hours
Duration of theraphy - thri
Sponsors
Institute of Psychiatry COE
Eligibility
Inclusion criteria
Inclusion criteria: (1) Subjects were male or female (postmenopausal, surgically sterile, or negative pregnancy test at screening and agreement to utilize an established birth control, including complete abstinence, during the testing period) between the age of 18 and 65 yrs. (2) All subjects had a DSM V-TR diagnosis of Obsessive Compulsive Disorder by structured clinical interview (SCID), with a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score >24 (26, 27). (3) OCD was treatment-refractory, as defined by a Y-BOCS >24 despite two SSRI trials of adequate dose and duration and having been offered prior CBT treatment. (4) Subjects were required to have had stable doses of all psychiatric medications for the month prior to treatment and have had no changes of dosage of SSRIs or clomipramine for at least 2 months prior to study enrollment. Most subjects received their treatment elsewhere; doses and duration of previous medication trials were verified through consultation with treating psychiatrists and review of past medical and pharmacy records. 5) Subjects were medically and neurologically healthy on the basis of physical examination, medical laboratory assessment, EKG, and medical history. Individuals with stable medical conditions or taking medications without major CNS effects (e.g., oral hypoglycemics) were eligible if their medications had not been adjusted in the month prior to entry. (6) Subjects could have no lifetime history of substance dependence diagnosis by SCID (excluding tobacco)
Exclusion criteria
Exclusion criteria: 1)Subject with comorbid depression, psychosis and any organic cause resulting in psychiatric manifestation 2)Current substance abuse or alcohol dependence in past month 3)Mental retardation, pervasive developmental disorder, 4)Epilepsy and other neurological disorder 5)Any other co-morbid psychiatric illness 6)Hypertension/ cardiac morbidity 7)Raised intracranial tension 8)Acute or chronic debilitating physical illness 9)Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A rapid improvement of obsessive compulsive symptoms amongst patient who are yet not responding to oral medicine.Timepoint: 1.5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| To see the effect of ketamine as an additional therapeutic tool in treatment resistant obsessive compulsive disorder with regards to placeboTimepoint: 1.5 years | — |
Countries
India
Contacts
Public ContactSuman Sarangi
Institute of Postgraduate Medical Education and Research
Outcome results
None listed